A single-cell transcriptomic landscape of innate and adaptive intratumoral immunity in triple negative breast cancer during chemo- and immunotherapies.


Journal

Cell death discovery
ISSN: 2058-7716
Titre abrégé: Cell Death Discov
Pays: United States
ID NLM: 101665035

Informations de publication

Date de publication:
08 Mar 2022
Historique:
received: 08 12 2021
accepted: 11 02 2022
revised: 03 02 2022
entrez: 9 3 2022
pubmed: 10 3 2022
medline: 10 3 2022
Statut: epublish

Résumé

Breast cancer (BC) constitutes a major health problem worldwide, making it the most common malignancy in women. Current treatment options for BC depend primarily on histological type, molecular markers, clinical aggressiveness and stage of disease. Immunotherapy, such as αPD-1, have shown combinatorial clinical activity with chemotherapy in triple negative breast cancer (TNBC) delineating some therapeutic combinations as more effective than others. However, a clear overview of the main immune cell populations involved in these treatments has never been provided.Here, an assessment of the immune landscape in the tumor microenvironment (TME) of two TNBC mouse models has been performed using single-cell RNA sequencing technology. Specifically, immune cells were evaluated in untreated conditions and after treatments with chemotherapy or immunotherapy used as single agents or in combination. A decrease of Treg was found in treatments with in vivo efficacy as well as γδ T cells, which have a pro-tumoral activity in mice. Focusing on Cd8 T cells, across all the conditions, a general increase of exhausted-like Cd8 T cells was confirmed in pre-clinical treatments with low efficacy and an opposite trend was found for the proliferative Cd8 T cells. Regarding macrophages, M2-like cells were enriched in treatments with low efficacy while M1-like macrophages followed an opposite trend. For both models, similar proportions of B cells were detected with an increase of proliferative B cells in treatments involving cisplatin in combination with αPD-1. The fine-scale characterization of the immune TME in this work can lead to new insights on the diagnosis and treatment of TNBC.

Identifiants

pubmed: 35260564
doi: 10.1038/s41420-022-00893-x
pii: 10.1038/s41420-022-00893-x
pmc: PMC8904804
doi:

Types de publication

Journal Article

Langues

eng

Pagination

106

Subventions

Organisme : Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research)
ID : IG20109

Informations de copyright

© 2022. The Author(s).

Références

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J Clin. 2021;71:209–49.
Kalimutho M, Parsons K, Mittal D, López JA, Srihari S, Khanna KK. Targeted therapies for triple-negative breast cancer: combating a stubborn disease. Trends Pharmacol. Sci. 2015;36:822–46.
pubmed: 26538316 doi: 10.1016/j.tips.2015.08.009
Korkmaz A, Topal T, Oter S. Pathophysiological aspects of cyclophosphamide and ifosfamide induced hemorrhagic cystitis; implication of reactive oxygen and nitrogen species as well as PARP activation. Cell Biol Toxicol. 2007;23:303–12.
pubmed: 17225077 doi: 10.1007/s10565-006-0078-0
Rosenberg B, Vancamp L, Trosko JE, Mansour VH. Platinum compounds: a new class of potent antitumour agents. Nature. 1969;222:385–6.
pubmed: 5782119 doi: 10.1038/222385a0
Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004;4:253–65.
pubmed: 15057285 doi: 10.1038/nrc1317
Gewirtz D. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. Pharmacol. 1999;57:727–41.
pubmed: 10075079 doi: 10.1016/S0006-2952(98)00307-4
Seidel JA, Otsuka A, Kabashima K. Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations. Front Oncol.2018;8:86
pubmed: 29644214 pmcid: 5883082 doi: 10.3389/fonc.2018.00086
Heimes A-S, Schmidt M. Atezolizumab for the treatment of triple-negative breast cancer. Expert Opin Investig Drugs. 2019;28:1–5.
pubmed: 30474425 doi: 10.1080/13543784.2019.1552255
Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23.
pubmed: 20525992 pmcid: 3549297 doi: 10.1056/NEJMoa1003466
Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387:1909–20.
pubmed: 26952546 pmcid: 5480242 doi: 10.1016/S0140-6736(16)00561-4
Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the Pd-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192:1027–34.
pubmed: 11015443 pmcid: 2193311 doi: 10.1084/jem.192.7.1027
Yearley JH, Gibson C, Yu N, Moon C, Murphy E, Juco J, et al. PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer. Clin Cancer Res. 2017;23:3158–67.
pubmed: 28619999 doi: 10.1158/1078-0432.CCR-16-1761
Seliger B. Basis of PD1/PD-L1 therapies. J Clin Med. 2019;8:2168.
pmcid: 6947170 doi: 10.3390/jcm8122168
Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020;10:727–42.
pubmed: 32266087 pmcid: 7136921
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–64.
pubmed: 22437870 pmcid: 4856023 doi: 10.1038/nrc3239
Yi JS, Cox MA, Zajac AJ. T-cell exhaustion: characteristics, causes and conversion. Immunology. 2010;129:474–81.
pubmed: 20201977 pmcid: 2842494 doi: 10.1111/j.1365-2567.2010.03255.x
Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med. 2009;206:3015–29.
pubmed: 20008522 pmcid: 2806460 doi: 10.1084/jem.20090847
Zhu Y, Zhu X, Tang C, Guan X, Zhang W. Progress and challenges of immunotherapy in triple-negative breast cancer. Biochim Biophys Acta (BBA) - Rev Cancer. 2021;1876:188593.
doi: 10.1016/j.bbcan.2021.188593
Chen H, Ye F, Guo G. Revolutionizing immunology with single-cell RNA sequencing. Cell Mol Immunol. 2019;16:242–9.
pubmed: 30796351 pmcid: 6460502 doi: 10.1038/s41423-019-0214-4
Haque A, Engel J, Teichmann SA, Lönnberg T. A practical guide to single-cell RNA-sequencing for biomedical research and clinical applications. Genome Med. 2017;9:75.
pubmed: 28821273 pmcid: 5561556 doi: 10.1186/s13073-017-0467-4
Orecchioni S, Talarico G, Labanca V, Calleri A, Mancuso P, Bertolini F. Vinorelbine, cyclophosphamide and 5-FU effects on the circulating and intratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma. Br J Cancer. 2018;118:1329–36.
pubmed: 29695766 pmcid: 5959935 doi: 10.1038/s41416-018-0076-z
Falvo P, Orecchioni S, Hillje R, Raveane A, Mancuso P, Camisaschi C, et al. Cyclophosphamide and vinorelbine activate stem-like CD8+ T cells and improve anti-PD-1 efficacy in triple-negative breast cancer. Cancer Res. 2021;81:685–97.
pubmed: 33268528 doi: 10.1158/0008-5472.CAN-20-1818
Reggiani F, Labanca V, Mancuso P, Rabascio C, Talarico G, Orecchioni S, et al. Adipose progenitor cell secretion of GM-CSF and MMP9 promotes a stromal and immunological microenvironment that supports breast cancer progression. Cancer Res. 2017;77:5169–82.
pubmed: 28754674 doi: 10.1158/0008-5472.CAN-17-0914
Mölder F, Jablonski KP, Letcher B, Hall MB, Tomkins-Tinch CH, Sochat V, et al. Sustainable data analysis with Snakemake. F1000Res. 2021;10:33.
pubmed: 34035898 pmcid: 8114187 doi: 10.12688/f1000research.29032.2
Hao Y, Hao S, Andersen-Nissen E, Mauck WM, Zheng S, Butler A, et al. Integrated analysis of multimodal single-cell data. Cell. 2021;184:3573. e29
pubmed: 34062119 pmcid: 8238499 doi: 10.1016/j.cell.2021.04.048
Germain P-L, Lun A, Macnair W, Robinson MD. Doublet identification in single-cell sequencing data using scDblFinder. F1000Research. 2021;10:979.
doi: 10.12688/f1000research.73600.1
Amezquita RA, Lun ATL, Becht E, Carey VJ, Carpp LN, Geistlinger L, et al. Orchestrating single-cell analysis with bioconductor. Nat Methods. 2020;17:137–45.
pubmed: 31792435 doi: 10.1038/s41592-019-0654-x
Wu J, Waxman DJ. Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8+ T-cell responses and immune memory. OncoImmunology. 2015;4:e1005521.
pubmed: 26137402 pmcid: 4485826 doi: 10.1080/2162402X.2015.1005521
Pfirschke C, Engblom C, Rickelt S, Cortez-Retamozo V, Garris C, Pucci F, et al. Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy. Immunity. 2016;44:343–54.
pubmed: 26872698 pmcid: 4758865 doi: 10.1016/j.immuni.2015.11.024
Trail PA, Willner D, Bianchi AB, Henderson AJ, TrailSmith MD, Girit E, et al. Enhanced antitumor activity of paclitaxel in combination with the anticarcinoma immunoconjugate BR96-doxorubicin. Clin Cancer Res. 1999;5:3632–8.
pubmed: 10589780
Rainer J, Gatto L, Weichenberger CX. ensembldb: an R package to create and use Ensembl-based annotation resources. Bioinformatics. 2019;35:3151–3.
pubmed: 30689724 pmcid: 6736197 doi: 10.1093/bioinformatics/btz031
Zappia L, Oshlack A. Clustering trees: a visualization for evaluating clusterings at multiple resolutions. GigaScience. 2018;7:giy083.
pmcid: 6057528 doi: 10.1093/gigascience/giy083
Aran D, Looney AP, Liu L, Wu E, Fong V, Hsu A, et al. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat Immunol. 2019;20:163–72.
pubmed: 30643263 pmcid: 6340744 doi: 10.1038/s41590-018-0276-y
Frankish A, Diekhans M, Ferreira A-M, Johnson R, Jungreis I, Loveland J, et al. GENCODE reference annotation for the human and mouse genomes. Nucleic Acids Res. 2019;47:D766–D773.
pubmed: 30357393 doi: 10.1093/nar/gky955
Franzén O, Gan L-M, Björkegren JLM. PanglaoDB: a web server for exploration of mouse and human single-cell RNA sequencing data. Database. 2019;2019:baz046.
pubmed: 30951143 pmcid: 6450036 doi: 10.1093/database/baz046
Finak G, McDavid A, Yajima M, Deng J, Gersuk V, Shalek AK, et al. MAST: a flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data. Genome Biol. 2015;16:278.
pubmed: 26653891 pmcid: 4676162 doi: 10.1186/s13059-015-0844-5
Johnsson K Intrinsic Dimension and Cluster Analysis. Centre for Mathematical Sciences, Lund University, 2016. 188 p.
Germain P-L, Sonrel A, Robinson MD. pipeComp, a general framework for the evaluation of computational pipelines, reveals performant single cell RNA-seq preprocessing tools. Genome Biol. 2020;21:227.
pubmed: 32873325 pmcid: 7465801 doi: 10.1186/s13059-020-02136-7
Glaros V, Rauschmeier R, Artemov AV, Reinhardt A, Ols S, Emmanouilidi A, et al. Limited access to antigen drives generation of early B cell memory while restraining the plasmablast response. Immunity. 2021;54:2005–23. e10
pubmed: 34525339 doi: 10.1016/j.immuni.2021.08.017
Hu Q, Hong Y, Qi P, Lu G, Mai X, Xu S, et al. Atlas of breast cancer infiltrated B-lymphocytes revealed by paired single-cell RNA-sequencing and antigen receptor profiling. Nat Commun. 2021;12:2186.
pubmed: 33846305 pmcid: 8042001 doi: 10.1038/s41467-021-22300-2
Wisdom AJ, Mowery YM, Hong CS, Himes JE, Nabet BY, Qin X, et al. Single cell analysis reveals distinct immune landscapes in transplant and primary sarcomas that determine response or resistance to immunotherapy. Nat Commun. 2020;11:6410.
pubmed: 33335088 pmcid: 7746723 doi: 10.1038/s41467-020-19917-0
Zhang Y, Chen H, Mo H, Hu X, Gao R, Zhao Y, et al. Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer. Cancer Cell. 2021;39:1578–93.
pubmed: 34653365 doi: 10.1016/j.ccell.2021.09.010
Street K, Risso D, Fletcher RB, Das D, Ngai J, Yosef N, et al. Slingshot: cell lineage and pseudotime inference for single-cell transcriptomics. BMC Genomics. 2018;19:477.
pubmed: 29914354 pmcid: 6007078 doi: 10.1186/s12864-018-4772-0
Rei M, Pennington DJ, Silva-Santos B. The emerging protumor role of γδ T lymphocytes: implications for cancer immunotherapy. Cancer Res. 2015;75:798–802.
pubmed: 25660949 doi: 10.1158/0008-5472.CAN-14-3228
Campbell KR, Yau C. Uncovering pseudotemporal trajectories with covariates from single cell and bulk expression data. Nat Commun. 2018;9:2442.
pubmed: 29934517 pmcid: 6015076 doi: 10.1038/s41467-018-04696-6
La Manno G, Soldatov R, Zeisel A, Braun E, Hochgerner H, Petukhov V, et al. RNA velocity of single cells. Nature. 2018;560:494–8.
pubmed: 30089906 pmcid: 6130801 doi: 10.1038/s41586-018-0414-6
Trapnell C, Cacchiarelli D, Grimsby J, Pokharel P, Li S, Morse M, et al. The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells. Nat Biotechnol. 2014;32:381–6.
pubmed: 24658644 pmcid: 4122333 doi: 10.1038/nbt.2859
Bassez A, Vos H, Van Dyck L, Floris G, Arijs I, Desmedt C, et al. A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer. Nat Med. 2021;27:820–32.
pubmed: 33958794 doi: 10.1038/s41591-021-01323-8
Silva-Santos B, Serre K, Norell H. γδ T cells in cancer. Nat Rev Immunol. 2015;15:683–91.
pubmed: 26449179 doi: 10.1038/nri3904
Rei M, Gonçalves-Sousa N, Lança T, Thompson RG, Mensurado S, Balkwill FR, et al. Murine CD27(−) Vγ6(+) γδ T cells producing IL-17A promote ovarian cancer growth via mobilization of protumor small peritoneal macrophages. Proc Natl Acad Sci USA. 2014;111:E3562–E3570.
pubmed: 25114209 pmcid: 4151711 doi: 10.1073/pnas.1403424111
Shechter R, Miller O, Yovel G, Rosenzweig N, London A, Ruckh J, et al. Recruitment of beneficial M2 macrophages to injured spinal cord is orchestrated by remote brain choroid plexus. Immunity. 2013;38:555–69.
pubmed: 23477737 pmcid: 4115271 doi: 10.1016/j.immuni.2013.02.012
Grzywa TM, Sosnowska A, Matryba P, Rydzynska Z, Jasinski M, Nowis D, et al. Myeloid cell-derived arginase in cancer immune response. Front Immunol. 2020;11:938.
pubmed: 32499785 pmcid: 7242730 doi: 10.3389/fimmu.2020.00938
Ni G, Yang X, Li J, Wu X, Liu Y, Li H, et al. Intratumoral injection of caerin 1.1 and 1.9 peptides increases the efficacy of vaccinated TC-1 tumor-bearing mice with PD-1 blockade by modulating macrophage heterogeneity and the activation of CD8+ T cells in the tumor microenvironment. Clin Transl Immunol. 2021;10:e1335.
doi: 10.1002/cti2.1335
Qu Y, Wen J, Thomas G, Yang W, Prior W, He W, et al. Baseline frequency of inflammatory Cxcl9-expressing tumor-associated macrophages predicts response to avelumab treatment. Cell Rep. 2020;32:107873.
pubmed: 32640238 doi: 10.1016/j.celrep.2020.107873
Samstein RM, Krishna C, Ma X, Pei X, Lee K-W, Makarov V, et al. Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy. Nat Cancer. 2020;1:1188–203.
pubmed: 33834176 pmcid: 8023400 doi: 10.1038/s43018-020-00139-8
Wu Y, Deng Y, Zhu J, Duan Y, Weng W, Wu X. Pim1 promotes cell proliferation and regulates glycolysis via interaction with MYC in ovarian cancer. Onco Targets Ther. 2018;11:6647–56.
pubmed: 30349298 pmcid: 6186298 doi: 10.2147/OTT.S180520
Gong L, Kwong DL-W, Dai W, Wu P, Li S, Yan Q, et al. Comprehensive single-cell sequencing reveals the stromal dynamics and tumor-specific characteristics in the microenvironment of nasopharyngeal carcinoma. Nat Commun. 2021;12:1540.
pubmed: 33750785 pmcid: 7943808 doi: 10.1038/s41467-021-21795-z
Park JH, Lee HK. Function of γδ T cells in tumor immunology and their application to cancer therapy. Exp Mol Med. 2021;53:318–27.
pubmed: 33707742 pmcid: 8080836 doi: 10.1038/s12276-021-00576-0
Kamphorst AO, Pillai RN, Yang S, Nasti TH, Akondy RS, Wieland A, et al. Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients. Proc Natl Acad Sci USA. 2017;114:4993–8.
pubmed: 28446615 pmcid: 5441721 doi: 10.1073/pnas.1705327114
Lin Y, Xu J, Lan H. Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications. J Hematol Oncol. 2019;12:76.
pubmed: 31300030 pmcid: 6626377 doi: 10.1186/s13045-019-0760-3
Griss J, Bauer W, Wagner C, Simon M, Chen M, Grabmeier-Pfistershammer K, et al. B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma. Nat Commun. 2019;10:4186.
pubmed: 31519915 pmcid: 6744450 doi: 10.1038/s41467-019-12160-2
GuhaThakurta D, Sheikh NA, Fan L-Q, Kandadi H, Meagher TC, Hall SJ, et al. Humoral immune response against nontargeted tumor antigens after treatment with Sipuleucel-T and its association with improved clinical outcome. Clin Cancer Res. 2015;21:3619–30.
pubmed: 25649018 pmcid: 4868054 doi: 10.1158/1078-0432.CCR-14-2334

Auteurs

Laura Carpen (L)

Laboratory of Hematology-Oncology, European Institute of Oncology IRCCS, Milan, Italy.
Human Technopole, Milan, Italy.

Paolo Falvo (P)

Laboratory of Hematology-Oncology, European Institute of Oncology IRCCS, Milan, Italy.

Stefania Orecchioni (S)

Laboratory of Hematology-Oncology, European Institute of Oncology IRCCS, Milan, Italy.

Giulia Mitola (G)

Laboratory of Hematology-Oncology, European Institute of Oncology IRCCS, Milan, Italy.

Roman Hillje (R)

The Hyve, Utrecht, Netherlands.

Saveria Mazzara (S)

Hematopathology Unit, European Institute of Oncology IRCCS, Milan, Italy.

Patrizia Mancuso (P)

Laboratory of Hematology-Oncology, European Institute of Oncology IRCCS, Milan, Italy.

Stefano Pileri (S)

Laboratory of Hematology-Oncology, European Institute of Oncology IRCCS, Milan, Italy.

Alessandro Raveane (A)

Laboratory of Hematology-Oncology, European Institute of Oncology IRCCS, Milan, Italy. alessandro.raveane@fht.org.
Human Technopole, Milan, Italy. alessandro.raveane@fht.org.

Francesco Bertolini (F)

Laboratory of Hematology-Oncology, European Institute of Oncology IRCCS, Milan, Italy. francesco.bertolini@ieo.it.

Classifications MeSH